Uma Sinha's most recent trade in ProKidney Corp - Ordinary Shares - Class A was a trade of 125,862 Director stock option (right to buy) done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ProKidney Corp - Ordinary ... | Uma Sinha | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 125,862 | 125,862 | - | - | Director stock option (right to buy) | |
| ProKidney Corp - Ordinary ... | Uma Sinha | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 62,558 | 62,558 | - | - | Director stock option (right to buy) | |
| ProKidney Corp - Ordinary ... | Uma Sinha | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 48,128 | 48,128 | - | - | Director stock option (right to buy) | |
| ProKidney Corp - Ordinary ... | Uma Sinha | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 30,000 | 30,000 | - | 0 | Class A Ordinary Shares | |
| BridgeBio Pharma Inc | Uma Sinha | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2020 | 10,832 | 10,832 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Uma Sinha | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2020 | 8,912 | 8,912 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Uma Sinha | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2020 | 5,717 | 5,717 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Uma Sinha | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 469 | 16,460 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Uma Sinha | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 469 | 6,563 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Uma Sinha | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2020 | 468 | 7,032 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Uma Sinha | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2020 | 468 | 15,991 (0%) | 0% | - | Common Stock |